Questions discussed in this category
Does the site of treatment factor into your decision?
Would you consider SBRT and continue osimertinib?
Are there specific mutations or co-mutations were you would consider use of this agent?
1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...
Would you continue osimertinib after radiation therapy, switch to crizotinib, or consider chemotherapy +/- immunotherapy?
The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...
89488762738763856766170958253453742
Papers discussed in this category
The New England journal of medicine, 2015-10-22
The New England journal of medicine, 2016-11-10
J Thorac Oncol,
Clin. Cancer Res., 2015 May 27
Lancet (London, England), 2017-01-21
Lancet (London, England), 2016-04-09
The New England journal of medicine, 2018-06-14
The Lancet. Respiratory medicine, 2019-05
Ann. Oncol.,
The New England journal of medicine, 2018-12-13
J. Clin. Oncol., 2019 Dec 11
Lancet Oncol., 2017 Sep 25
Clin Oncol (R Coll Radiol), 2017 Nov 16
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06